Abstract
The rapid spread of obesity and associated cardiovascular disease is of serious concern in the scientific and medical field. Despite diverse approaches to solving these problems, there is still no visible success in the fight against obesity at the population level, and cardiovascular pathology still remains one of the main causes of death and disability in the world. This leads to attempts aimed at finding new therapeutic options. Targeted pharmacological therapy for adipose tissue dysfunction represents one of the potential solutions. In the present article, we review the effects of adipocytokines such as adiponectin and leptin, as one of the most well-studied markers of disruption of the normal functioning of adipose tissue, as well as some modern approaches to pharmacological correction of their effects on the cardiovascular system. The analysis of the data shows that hypoadiponectinemia and hyperleptinemia in combination with leptin resistance are associated with cardiovascular disease and poor prognosis, and correction of pathologically altered levels of the above-mentioned adipocytokines to achieve their optimal ratio may represent a relevant therapeutic goal.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
